1. Overview
  2. All Stocks
  3. Xeris Pharmaceuticals, Inc

Xeris Pharmaceuticals (XERS.US) Price Target 2026/2027: 30% Upside – Rating and Stock Analysis

9.44
-1.31%
Analysis framework by , founder of TradeDesk · Data: EODHD, insider trades from SEC Form 4 filings · Updated
Share this analysis:

Xeris Pharmaceuticals Price Target 2026: Analysts See 30% Upside

The average price target for Xeris Pharmaceuticals is $12.29. This price target represents the analysts' view of the stock price over the next 12 months. The stock may be undervalued, because the price target is higher than the current price. The stock is 30.26% below the target, which can point to potential returns within the next 12 months if the analysts' view proves right. Also consider the stock's valuation ratios such as P/E, P/S and P/B, plus the technical analysis further down the page, for the full picture.

Is Xeris Pharmaceuticals overvalued or undervalued?

Xeris Pharmaceuticals is currently undervalued with a gap of 30.3% relative to the price target.


The current price is $9.44, which places Xeris Pharmaceuticals in the undervalued category. The stock is considered undervalued when the price is below $11.06, and overvalued when the price exceeds $13.52.


The fair value range is defined as ±10% of the price target, because price targets are estimates rather than exact values. For Xeris Pharmaceuticals, the fair value range lies between $11.06 and $13.52.


See the full price target analysis for Xeris Pharmaceuticals →

↑ Back to navigation

Analyst Ratings for Xeris Pharmaceuticals stock in 2026: Strong Buy

6 analysts cover Xeris Pharmaceuticals. There is broad agreement on a positive view — 83.4% recommend buying. The average price target is $12.29, which gives an upside of 30.3% from the current price.

Consensus: Strong Buy (4.50/5)
Strong Buy
4 (66.7%)
Buy
1 (16.7%)
Hold
1 (16.7%)
Strong Sell Sell Hold Buy Strong Buy
4.50 out of 5 based on 6 analysts
↑ Back to navigation

About Xeris Pharmaceuticals – Drug Manufacturers - Specialty & Generic

Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois. Read more about the company

Key Figures for Xeris Pharmaceuticals

$1.7B Market cap
$335M Revenue
Drug Manufacturers - Specialty & Generic Industry
- P/E
5.20 P/S
107.68 P/B
United States Listed on exchange
xerispharma.com Website
Healthcare Sector

What kind of stock is Xeris Pharmaceuticals?

Speculative stock

Xeris Pharmaceuticals is classified as a speculative stock.

Score Overview for Xeris Pharmaceuticals

💰 Value Score 8/100 (Very Low)
⭐ Quality Score 47/100 (Neutral)
📊 Total Score 18/100

⚠️ 4 red flags identified 3 critical

Our analysis has identified 4 potential risk factors in Xeris Pharmaceuticals that investors should be aware of.

🚨 High debt: The debt-to-equity ratio is 1,000% – the company carries considerably more debt than equity, which raises the financial risk.
🚨 Weak balance sheet (elevated risk): Altman Z2 is -4.14 – the balance sheet is measurably weaker than average. This is a risk signal based on the numbers, not a bankruptcy prediction.
⚠️ Negative profit margin: The profit margin is -5.1% – the company is losing money on its operations.
🚨 Negative return on equity: ROE is -617.2% – the company is generating a negative return for shareholders.

📈 Valuation

The P/S ratio is 5.2 (high — the market pays a premium for the revenue). The P/B ratio is 107.7.

💵 Profitability & Growth

Xeris Pharmaceuticals and an operating margin of 5.6%. Return on assets (ROA) is 6.1%.

🏦 Financial Health

The Piotroski score is 7 out of 9 — good financial health. Altman Z2 is -4.14 (weak balance sheet — elevated risk). The debt-to-equity ratio (D/E) is 1,000.0% — high debt, which raises the risk.

🚀 Momentum & Short Interest

Short interest is 4.57%.

↑ Back to navigation

Xeris Pharmaceuticals Short Selling 2026: 4.6% Sold Short

Moderate short interest: 4.6% of the free float
Short % of free float
4.6%
Assessment
Moderate short interest
Short squeeze risk
Low
Data source
EODHD
Reported about twice a month
The stock has a moderate share of short selling. Between 2-5% of the freely traded shares are sold short, which is within the normal range for most stocks.

Short interest comes from our data provider EODHD. The figure is reported about twice a month; we check it every trading day.
Short Interest Scale
0% 2% 5% 10% 20%+
Low Moderate High Very High Extreme
▲
4.6%

↑ Back to navigation

When Does Xeris Pharmaceuticals Report Earnings?

The next earnings date for Xeris Pharmaceuticals is not yet available. Check the company's investor calendar for more information.



↑ Back to navigation

Technical Analysis of Xeris Pharmaceuticals 2026 – Signal: Strong Buy

Overall Technical Signal: Strong Buy

Based on trend analysis (SMA50/SMA200) and MACD trend (positive/negative on a daily + weekly basis). Updated October 1, 2026.

Trend Analysis of Xeris Pharmaceuticals, Inc

Xeris Pharmaceuticals, Inc is in a short-term uptrend. The price of $9.56 is 12.6% above the 20-day average ($8.49). Medium term, the picture is positive: the price is 13.4% above the 50-day average ($8.43). Long term, the stock is 33.2% above the 200-day average ($7.18), which confirms a long-term uptrend.

Golden Cross: The 50-day average (8.43) is above the 200-day average (7.18), which is a classic bullish signal for Xeris Pharmaceuticals, Inc.

Is Xeris Pharmaceuticals, Inc overbought or oversold?

Xeris Pharmaceuticals, Inc has an RSI of 64.9. The stock shows positive momentum in the upper part of the neutral zone. Combined with the positive trend, this supports the bullish picture.

MACD Analysis for Xeris Pharmaceuticals, Inc

Daily MACD: MACD is positive (0.337), which means the short-term trend is bullish (the 12-day EMA is above the 26-day EMA). MACD is above the signal line (0.146) by 0.191, which confirms rising momentum in the uptrend.

Weekly MACD: MACD5 is positive (0.536), which indicates a broader bullish long-term trend. MACD5 is above the signal line (0.439) by 0.097, which confirms rising long-term momentum.

Overall MACD assessment: Both the daily and weekly MACD are positive and above their signal lines. Trend and momentum confirm each other across time horizons – the strongest bullish signal.

Risk Profile for Xeris Pharmaceuticals, Inc

Xeris Pharmaceuticals, Inc has an annual standard deviation of 0.0%, which classifies the stock as Conservative. Price swings are limited, and the stock suits conservative investors.

Overall Technical Conclusion for Xeris Pharmaceuticals, Inc

Trend: Positive. The price trades above SMA50 and SMA200.

MACD trend (zero line): Daily bullish (0.337). Weekly bullish (0.536).

MACD momentum (signal): Daily rising. Weekly rising.

RSI: 64.9 – neutral.

Technical signal: Strong Buy

The price is in an uptrend (above SMA50/SMA200) and MACD is positive on both a daily and weekly basis. Trend and MACD trend confirm each other – the strongest technical buy signal.

↑ Back to navigation

Frequently Asked Questions About Xeris Pharmaceuticals stock in 2026

Should you buy Xeris Pharmaceuticals stock now?
Yes, the technical signal for Xeris Pharmaceuticals is currently Strong Buy. Xeris Pharmaceuticals trades at $9.44 as of Oct 1, 2026. The technical analysis shows the following: MACD is positive (bullish trend) at 0.337 with rising momentum (signal: 0.146); RSI is at 64.9 (neutral zone); the stock is in a short-term uptrend (price above the 20-day average); the analyst price target of $12.29 points to 30.3% upside. The stock is in a broader uptrend (above SMA50/SMA200). This is a technical observation based on current data, not investment advice.
What is the price target for Xeris Pharmaceuticals stock?
The average analyst price target for Xeris Pharmaceuticals is $12.29. The current price is $9.44, which gives an upside of 30.3%. Based on this, the stock is considered undervalued. The fair value range (±10% of the price target) is between $11.06 and $13.52.
Is Xeris Pharmaceuticals a dividend stock?
No, Xeris Pharmaceuticals does not currently pay a dividend to shareholders. The company reinvests its profits in growth instead of paying dividends.
What is the risk of Xeris Pharmaceuticals stock?
Xeris Pharmaceuticals is rated as a stock in the risk category Conservative. the annual standard deviation is 0.0%, which classifies the stock as Conservative.
Is Xeris Pharmaceuticals overvalued?
No, Xeris Pharmaceuticals is considered undervalued based on the analyst price target (30.3% upside). Xeris Pharmaceuticals has the following valuation ratios: a P/S ratio of 5.2, a P/B ratio of 107.7. The analyst price target suggests that the stock is undervalued by 30.3%.
Is Xeris Pharmaceuticals overbought?
No, Xeris Pharmaceuticals is not overbought. RSI is at 64.9 (neutral zone). The technical indicators show: RSI is at 64.9 (upper neutral zone), which shows positive momentum but is not yet overbought. In addition, the price is 11.1% above the 20-day average (short-term uptrend). In addition, MACD is positive with rising momentum (bullish).
When is the next Xeris Pharmaceuticals earnings report?
The date of the next earnings report for Xeris Pharmaceuticals has not been published yet. Check the company's investor calendar for updates.
Is Xeris Pharmaceuticals shorted?
Yes, Xeris Pharmaceuticals is shorted with 4.6% of the free float sold short. This is a moderate level of short selling, within the normal range for most stocks. The figure comes from our data provider EODHD, is reported about twice a month, and we check it every trading day.
Are insiders buying Xeris Pharmaceuticals stock?
There is currently no registered insider trading for Xeris Pharmaceuticals.
Is Xeris Pharmaceuticals a good stock?
Based on our total score, Xeris Pharmaceuticals is rated as a disastrous stock with a total score of 18 out of 100. The stock scores very low on value, quality and momentum – it is among the worst in our database. The score is made up of Value: 8/100, Quality: 47/100. In addition: analysts see 30.3% upside to the price target; technical signal: Strong Buy. Whether Xeris Pharmaceuticals is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for Xeris Pharmaceuticals stock?
The outlook for Xeris Pharmaceuticals based on current data: the average analyst price target is $12.29 (+30.3%); the stock is in an uptrend (above SMA50 and SMA200). Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is Xeris Pharmaceuticals stock rising?
Xeris Pharmaceuticals is rising right now. The technical indicators show: the price is 11.1% above the 20-day average; MACD is positive with rising momentum (bullish signal). For the latest context, see our technical analysis and insider section above.
How high can Xeris Pharmaceuticals go?
The average analyst price target for Xeris Pharmaceuticals is $12.29, which corresponds to a potential gain of 30.3% from the current price of $9.44. The stock has traded between $5.25 and $11.33 over the last 52 weeks. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can Xeris Pharmaceuticals fall?
The stock has traded as low as $5.25 over the last 52 weeks — that is 44.4% below the current price of $9.44. The biggest decline (drawdown) in the same period was 53.7% from high to low. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash. Use stop-loss orders and spread your portfolio to limit losses in single stocks.
What does Xeris Pharmaceuticals do?
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hyp... The company belongs to the Healthcare sector, more specifically the Drug Manufacturers - Specialty & Generic industry, is headquartered in United States, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate Xeris Pharmaceuticals as an investment.
Did Xeris Pharmaceuticals raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from Xeris Pharmaceuticals. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history above.
Is Xeris Pharmaceuticals making money or losing money?
No, Xeris Pharmaceuticals is currently not making money — the company is losing money with a negative profit margin of -5.1%, a noticeable loss. That means the business loses money on every dollar of revenue. The operating margin, however, is positive at 5.6% — the core business makes money; the loss comes from financing costs, taxes or one-off items. For growth stocks investing in expansion this is normal — but it raises the risk if the company does not reach break-even before its capital runs out.
Can Xeris Pharmaceuticals go bankrupt?
The bankruptcy risk of Xeris Pharmaceuticals is rated as elevated. Altman Z2 (a model for assessing financial distress) is -4.14 — that places the company in the weak zone. This is a probability based on the numbers, not a verdict — bankruptcy is not imminent. But the balance sheet is measurably weaker than average, so watch the debt, liquidity and possible capital raises. The Piotroski score (financial health 0-9, higher is better) is 7 — which is strong. Debt relative to equity is 1,000% (high). Remember: models like Altman Z2 are statistical — unexpected shocks (fraud, a sector collapse, lawsuits) can always happen. Spread your portfolio.
Does Xeris Pharmaceuticals have a lot of debt?
Yes, Xeris Pharmaceuticals has elevated debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 1,000%. For the healthcare sector, anything above 150% counts as elevated — that raises the financial risk, especially if interest rates rise or earnings fall. In healthcare, 80-150% is typical — large pharma companies carry debt for research and acquisitions. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector. Can Xeris Pharmaceuticals service its debt? Could struggle to service its debt — the interest coverage ratio (how many times earnings can cover interest payments) is -3.5x, and net debt equals 3.4 years of earnings (EBITDA).
↑ Back to navigation

Other Stocks in Healthcare

Compare Xeris Pharmaceuticals with other stocks in the healthcare sector. Click a stock to see its technical analysis, insider trading and key figures.

See all 107 stocks in the Healthcare sector

Explore More